Caribou Biosciences Reports Q3 2026 Net Loss of $26.6 Million
Caribou reported a third-quarter net loss of $26.6 million, or $0.25 per share, versus a $27.5 million loss, or $0.30 per share, a year earlier. Revenue was $1.6 million; cash, equivalents and marketable securities totaled $94.8 million at September 30, 2026.
Caribou Biosciences reported a third-quarter 2026 net loss of $26.6 million, or $0.25 per share, compared with a $27.5 million loss, or $0.30 per share, a year earlier. Revenue was $1.6 million, while cash, cash equivalents, and marketable securities totaled $94.8 million at September 30, 2026. The…